Trial · NCT02264665
Participant flow35
How many started, completed or left each group, period by period.
1 to 20 of 35
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Everolimus (Targeted Therapy) at Inclusion | 35 | |
| Overall Study | STARTED | Sunitinib (Targeted Therapy) at Inclusion | 23 | |
| Overall Study | STARTED | Chemotherapy (Other Treatment) at Inclusion | 52 | |
| Overall Study | STARTED | Somatostatin Analogues (Other Treatment) at Inclusion | 30 | |
| Overall Study | STARTED | Metabolic Radiotherapy (Other Treatment) at Inclusion | 1 | |
| Overall Study | STARTED | Interferon-alpha (Other Treatment) at Inclusion | 0 | |
| Overall Study | STARTED | Treatment Not Documented | 3 | |
| Overall Study | Reference Set (Full Analysis Set) | Everolimus (Targeted Therapy) at Inclusion | 32 | |
| Overall Study | Reference Set (Full Analysis Set) | Sunitinib (Targeted Therapy) at Inclusion | 23 | |
| Overall Study | Reference Set (Full Analysis Set) | Chemotherapy (Other Treatment) at Inclusion | 50 | |
| Overall Study | Reference Set (Full Analysis Set) | Somatostatin Analogues (Other Treatment) at Inclusion | 28 | |
| Overall Study | Reference Set (Full Analysis Set) | Metabolic Radiotherapy (Other Treatment) at Inclusion | 1 | |
| Overall Study | Reference Set (Full Analysis Set) | Interferon-alpha (Other Treatment) at Inclusion | 0 | |
| Overall Study | Reference Set (Full Analysis Set) | Treatment Not Documented | 0 | |
| Overall Study | Safety Set | Everolimus (Targeted Therapy) at Inclusion | 35 | |
| Overall Study | Safety Set | Sunitinib (Targeted Therapy) at Inclusion | 23 | |
| Overall Study | Safety Set | Chemotherapy (Other Treatment) at Inclusion | 52 | |
| Overall Study | Safety Set | Somatostatin Analogues (Other Treatment) at Inclusion | 30 | |
| Overall Study | Safety Set | Metabolic Radiotherapy (Other Treatment) at Inclusion | 1 | |
| Overall Study | Safety Set | Interferon-alpha (Other Treatment) at Inclusion | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02264665/flow